Bone Marrow Transplantation and the Potential Role of Iomab-B - PowerPoint PPT Presentation

Bone Marrow Transplantation and the Potential Role of Iomab-B Hillard M. Lazarus, MD, FACP Professor of Medicine, Director of Novel Cell Therapy Case Western Reserve University 1

Hematopoietic Cell Transplantation (HCT) Background • Life-saving art applied for: – Hematologic malignancy (most common indication) – Goal: eliminate malignancy – Acquired and genetic disorders of hematopoiesis and the immune system – Goal: restore normal blood production/immunity • Premise(s): – Cytotoxic agents required to turn off recipient’s immune system and allow engraftment (avoid rejection) – Increasing doses of cytotoxic agents (chemotherapy, radiotherapy) markedly increase cancer cell kill • BUT cytotoxics harm blood cell production (marrow injury) • Leads potentially to fatal infection and bleeding 2

Hematopoietic Cell Transplantation (HCT) Background ( cont’d) • Infusion of hematopoietic progenitor cells “rescue” host • Cells obtained from: – patient himself/herself (autologous) or – another person (allogeneic) • Hematopoiesis restored over several weeks by infused cells • Requires that recipient has been given vigorous supportive care with antibiotics, transfusions, other tools 3

Hematopoietic Cell Transplantation (HCT) Background ( cont’d) • HCT can be divided into many types; depends on: • Intensity of chemo-radiation therapy given: – myeloablative – reduced-intensity conditioning – non-myeloablative 4

Hematopoietic Cell Transplantation (HCT) Background (cont’d) • Donor graft, related and unrelated: – Autologous (self) – Allogeneic (another person) – Related: histo-compatible (HLA-identical) sibling – Theoretically best donor – Related: haplo- identical (“half - match” family member) – At present, much less commonly used – Alternative donor (not related) – Unrelated (but histo-compatible, i.e. HLA-identical) adult – Umbilical cord blood (obtained from the placenta after delivery) 5

Hematopoietic Cell Transplantation (HCT) Background ( cont’d) • Graft source – Bone marrow (collected in OR from post-iliac crests) – Blood (marrow progenitors mobilized into blood using agents, collected via large catheter (85% of all HCT) – umbilical cord blood (from the placenta after delivery) • Advantages/disadvantages for these various approaches – Depends on disorder affecting recipient – Donor availability – Age and physical condition of the recipient – Planned timing of transplant – Many other factors 6

Autologous Hematopoietic Cell Transplant Chronology of Approach Stem Cell: Vigorous Collection Patient High-dose Infusion Supportive ± Purging Evaluation Chemotherapy of Graft Care Freezing 7

Allogeneic Hematopoietic Cell Transplant Chronology of Approach Begin GvHD Vigorous Prophylaxis Patient High-dose Infusion Supportive Therapy: Evaluation Chemotherapy of Graft Care Immuno- suppression Hematopoietic Cell Donor Collection Evaluation ± T-cell depletion ± Freezing 8

Hematopoietic Cell Transplant Donor Availability and Transplant Type Match % All Donor Type Probability Transplants HLA-compatible sibling 30% 54% HLA-compatible unrelated 35-80% 38% Umbilical cord blood (UCB) 10-90% 5% Haploidentical 99% <5% C Anasetti. BMT CTN State-of-the-Science, June 2007, Ann Arbor, MI 9

Acute Myeloid Leukemia (AML) Survival by Age < 50 85+ Adapted from Juliusson G et al. Blood 2009;113:4179-4187 10

Rationale for RIT in HCT Regimens Relationship between Relapse and Dose AML is highly radiosensitive. ♦ TBI effective in HCT at high doses. ♦ TBI cannot be safely dose-escalated ♦ because normal organs cannot tolerate more radiation. Tradeoff: more killing of leukemia ♦ simultaneously destroys normal tissue. TBI = total body irradiation RIT = radioimmunotherapy 11

Conditioning Regimens for Allogeneic HCT Non-myeloablative Iomab-B Conditioning NMA Safety Reduced-Intensity Conditioning RIC Myeloablative Conditioning MA Efficacy = Tradeoff Zone; Safety versus Efficacy 12

Iomab-B Biodistribution Iomab-B combines an anti-CD45 mAb  that targets lympho-hematopoietic cells with a radio-toxin, the β -particle emitting radionuclide 131 I. RADIATION DOSE (cGy/mCi 131 I) The mAb does not bind to other normal  tissues and directs radiation to only leukemic and immune cells. MARROW SPLEEN LIVER LUNG KIDNEY TOTAL BODY Leukemia Leukemia Leukemia Normal Tissue cells cells cells 13 Blood 2009 114:5444-5453

Iomab-B: Targeted Radiation Enabling HCT ♦ Iomab- B is a “guided missile” which selectively ablates bone marrow, CD45 LEUKEMIA CELLS killing leukemia cells as well as host immune system cells (the latter prevents rejection of hematopoietic cells from another person) IV infusion Antibody targeting ♦ This therapy is part of the transplant regimen; must be followed immediately by infusion of a hematopoietic graft from another person to restore marrow function ♦ New marrow grows back over several weeks and blood production resumes Targeted ablation Bone marrow transplant 14

Iomab-B Phase I/II Results • Prior data from the Fred Hutchinson Cancer Research Center • Patients > 50 years old with advanced AML and high risk MDS • Patients received Iomab-B followed by hematopoietic cell transplant • N= 21; patients treated at MTD 1.0 0.9 Overall Survival 0.8 Disease - Free Survival Non - Relapse Mortality 0.7 Relapse 0.6 Probability Censor 0.5 0.4 0.3 0.2 0.1 0.0 0 0.5 1 1.5 2 2.5 3 3.5 4 Years after Transplant Adapted from Blood 2009 114:5444-5453 15

Iomab-B Phase I/II Results Definitions: Primary Refractory AML: ♦ – Leukemia is uncontrolled and resistant to treatment – No response seen after two cycles of induction attempts Myeloablation ♦ – Depletion of bone marrow; carries standard risks of infection and bleeding; – Patients are isolated and given vigorous supportive care, i.e. transfusions and antibiotics Complete Remission (CR): ♦ – No obvious evidence of leukemia – Recovery of white blood cells and platelets 16

Iomab-B Phase I/II Results Non-relapse mortality (NRM): Day 100<10%, Overall ~20% Complete response rate: 100% ♦ ♦ (NRM = 46% in comparable patients with conventional Engraftment by day 28: 100% ♦ myeloablative conditioning transplants * ) All relapsed/refractory AML patients over 50 35% Iomab-B BMT (N=27) 30% * Current BMT (N=10) 30% Chemotherapy (N=61) 25% Percentage Survival 19% 20% 15% 10% 10% 10% 5% 0% 0% 0% 1 year 2 years N = Number of patients treated. Iomab-B results from FHCRC clinical trials; Current BMT and Chemotherapy results from MD Anderson outcomes analysis 17 Sources: Blood 2009 114:5444-5453; unpublished FHCRC data

Iomab-B Phase I/II with Poor Cytogenetics Rel/ref AML patients over 50 w/ poor cytogenetics 35% 33% Iomab-B BMT (N=18) Current BMT (N=19) 30% Chemotherapy (N=95) 25% Percentage Survival 20% 16% 15% 10% 5% 3% 3% 0% 0% 0% 1 year 2 years N = Number of patients treated Iomab-B results from FHCRC clinical trials; Current BMT and Chemotherapy results from MD Anderson outcomes analysis 18 Sources: Blood 2009 114:5444-5453; unpublished FHCRC data

Iomab-B Pivotal Phase III Trial Design – Single pivotal study, pending trial results – Patient population: refractory AML patients over the age of 55 years – Trial arms: study arm and control arm with physician’s choice of conventional care with curative intent – Trial size: 150 patients total, 75 patients per arm – Study timeline: enrollment approximately 12 months; primary endpoint additional 8 months; secondary endpoint additional 4 months; follow-up 5 years Study Arm Off Study No CR Iomab-B Not Fail and enrolled R NMA/RIC Initial Observation CR A transplant Screening N Crossover * D Pass Enrolled O M No CR I Control Arm Z Current Treatments (Chemotherapy) E NMA/RIC** ATNM Drug Candidate CR and Positive Response HSCT Negative Response *Control arm subjects with no CR are offered crossover to Iomab-B for ethical reasons. **NMA/RIC = Nonmyeloablative Conditioning/Reduced Intensity Conditioning transplant 1. Based on the End of Phase II meeting and subsequent communications with the FDA. 2. Refractory is defined as either primary failure to achieve a complete remission after 2 cycles of induction therapy; relapsed after <6 months 19 in complete remission; second or higher relapse; or relapsed disease not responding to intensive salvage therapy

Appendix: Likelihood of Finding an 8/8 HLA Match In 2015, nearly every patient can have a donor. Gragert L et al. N Engl J Med 2014;371:339-348. 20